Breast Cancer Tumor Heterogeneity

UnknownOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 22, 2017

Study Completion Date

December 31, 2018

Conditions
Breast Cancer
Interventions
OTHER

Post Surgical Her2 testing

Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes

Trial Locations (1)

21401

Anne Arundel Medical Center, Annapolis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Anne Arundel Health System Research Institute

OTHER